Background {#Sec1}
==========

*HFE*-related hemochromatosis (or type 1 hemochromatosis; OMIM \#235200) is an inborn iron metabolism disorder that is particularly common in Caucasian populations \[[@CR1], [@CR2]\]. This genetic disease is characterised by an inappropriate high iron absorption from enterocytes and by an excessive iron release from macrophages. It is due to a defective regulation of the synthesis of hepcidin, the key regulator of iron homeostasis \[[@CR3]--[@CR5]\]. As human body is not capable of eliminating the excess of iron, this will gradually affect various organs and may result in serious damages, e.g. cirrhosis, hepatocellular carcinoma or cardiomyopathy \[[@CR6]\].

*HFE* hemochromatosis is inherited as an autosomal recessive trait and is mainly associated with the *HFE* p.\[Cys282Tyr\];\[Cys282Tyr\] genotype \[[@CR7]\]. The penetrance of this genotype is clearly incomplete \[[@CR8]--[@CR10]\], and its expression is influenced by genetic and environmental factors that may increase or reduce the iron burden \[[@CR8], [@CR11], [@CR12]\].

This expression of this genetic disorder is delayed in women than in men. Moreover, *HFE* hemochromatosis women present with a less severe clinical profile, notably a lower prevalence of liver injury \[[@CR13], [@CR14]\]. This difference between genders has classically been attributed to the protective effects mediated by iron losses related to menses and pregnancy \[[@CR15]--[@CR17]\].

During pregnancy, maternal iron requirements increase substantially to allow for the physiological expansion of the haemoglobin mass, to promote formation of the foetus and placenta, and to cope with blood losses at delivery \[[@CR18]\]. While it is commonly stated in the literature that these pregnancy-associated iron losses are one of the factors that offset the lifelong iron accumulation in women \[[@CR15]--[@CR17]\], this assertion has not been supported by any epidemiological studies in humans.

As recent literature has shown that other factors such as hormones may explain the differences observed according to gender \[[@CR19], [@CR20]\], we sought to investigate the association between pregnancy and the phenotypic expression of the predominant *HFE* p.\[Cys282Tyr\];\[Cys282Tyr\] genotype.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

This work evaluated a cohort of 140 consecutive p.Cys282Tyr homozygous hemochromatosis women who started phlebotomies between January 1st, 2004 and December 31st, 2011 at a blood centre in western Brittany (Brest, France) where this disease is particularly common \[[@CR21], [@CR22]\].

Included patients presented elevated iron markers (with transferrin saturation (TS) \> 45% and serum ferritin (SF) \> 200 μg/L) and were referred by general practitioners or gastroenterologists to the blood centre for phlebotomy.

Questionnaire {#Sec4}
-------------

This study relied on data obtained using a clinical questionnaire that was filled out upon admission to the phlebotomy program. As previously described \[[@CR22]\], this questionnaire, which was completed by a referral physician, collected information on socio-demographic characteristics (gender, age at diagnosis, etc.), lifestyle factors (height, weight, alcohol intake, etc.) and biological parameters (including transferrin saturation and serum ferritin).

It also recorded data on reproductive functions, on the presence (and number if any) of pregnancies prior to the beginning of the treatment (excluding miscarriages and abortions occurring in the first trimester), as well as on the menopausal status at admission to the phlebotomy program. Patients were also asked if they were regular blood donors, if they had chronic bleedings (including gastrointestinal bleedings, chronic hematuria, bleedings due to parasitic infections) and if they received blood transfusions (and how many if any), all this prior to admission to the phlebotomy program.

At the end of the depletion stage, treatment-related data (i.e. the number and average volume of the phlebotomies) were recorded. These data enable estimation of the amount of iron removed (AIR; in grams) to normalise patient's iron stores (i.e. to reach SF \< 100 μg/L). This calculation was performed assuming that 1 L of blood contains 0.5 g of iron \[[@CR23]\].

Statistical analysis {#Sec5}
--------------------

Statistical analysis was carried out using the SAS software (version 9.4; SAS Institute Inc., Cary, NC). All tests were performed two-sided, and the significance level was set at 5% for all analyses.

First, we described the baseline characteristics of the studied population. Continuous variables were described in means and standard deviation (SD), and were compared using Student's *t* test or Anova. When these variables were not normally distributed, they were described by median and interquartile range (IQR), and compared by the Mann-Whitney test. Categorical variables were summarised in percentages, and were compared using χ^2^ test or Fisher's exact test when appropriate.

Before assessing the influence of pregnancy, we explored the impact of gender on disease expression. For this, we compared the age at diagnosis of women in the study to that observed in the men cared for during the same period in our blood centre (*n* = 161) (using Student's *t* test). We also evaluated whether the proportion of diagnosed female patients increased with the age at diagnosis i.e. if the sex ratio ~(M/F)~ decreased with the age at diagnosis (using a linear trend χ^2^ test).

In a second time, we compared women characteristics according to their pregnancy status (number of previous pregnancies). We then investigated the association between pregnancy and the degree of iron overload (assessed by SF and AIR) using linear regression analysis. As the distributions of these quantitative dependant variables were highly skewed (Kolmogorov-Smirnov test), we performed logarithmic (ln) transformations to normalise them. With such a transformation, the exponential of the estimated regression coefficient (e^β^) indicates how many times the outcome variable varies for each unit increment in the explanatory variable. This means, in other words, that each unit increment in the explanatory variable multiplies the expected value of Y by e^β^. We then tested the association between the iron parameters and potential confounding factors such as age at diagnosis, alcohol intake (whose hepatotoxic effect increases the disease severity) \[[@CR24], [@CR25]\]) and menopausal status. We thereafter fitted a multivariable model to enable adjustment for confounders. All explanatory variables associated with the outcome variables at a conservative threshold of *P* \< 0.20 in the univariable analysis were included in this multivariable analysis.

In the present study, excessive alcohol intake was defined, in accordance with the World Health Organization definition, as daily consumption exceeding two glasses per day (i.e. 14 glasses per week) for women. Overweight status was defined as a body mass index (BMI) ≥ 25 kg/m^2^.

Results {#Sec6}
=======

Baseline characteristics of the study population {#Sec7}
------------------------------------------------

During the study period, 140 p.Cys282Tyr homozygous hemochromatosis women were enrolled into a phlebotomy program at the blood centre of Brest. The "pregnancy" variable was documented for 137 (97.9%) women and 127 of them (92.7%) completed the depletion phase during the study. The baseline characteristics of the women included in the study and for whom data on pregnancies was available are presented in Table [1](#Tab1){ref-type="table"}. These women were diagnosed in mean at the age of 52.5 years (± 14.0). Among them, 29.8% were overweight (BMI ≥ 25 kg/m^2^) and 4.5% declared having excessive alcohol consumption. More than 60% of the women were menopausal at entry into the phlebotomy program, with a mean age at menopause of 49.2 y. (± 4.3).Table 1Baseline characteristics of the p.Cys282Tyr homozygous hemochromatosis women according to the number of pregnancies that women had prior to entry into the phlebotomy programVariablesAll womenNumber of pregnancies: 0Number of pregnancies: 1 or 2Number of pregnancies: ≥ 3*P* ^*\**^*n*%*n*%*n*%*n*%Number of women137146558Age at diagnosis *(n = 137)*  ≥ 60 y^a^4129.9%214.3%1624.6%2339.7%0.077  \< 60 y.9670.1%1285.7%4975.4%3560.3%Body mass index *(n = 131)*  ≥ 25 kg/m^2^3929.8%214.3%1930.6%1832.7%0.395  \< 25 kg/m^2^9270.2%1285.7%4369.4%3767.3%Alcohol intake *(n = 134)* Excessive^b^64.5%00.0%23.1%47.0%0.418 Non excessive12895.5%13100.0%6296.9%5393.0%Menopause *(n = 126)* Yes8063.5%321.4%3666.7%4170.7%0.002 No4636.5%1178.6%1833.3%1729.3%Regular blood donations *(n = 136)* Yes3727.2%535.7%1523.1%1729.8%0.530 No9972.8%964.3%5076.9%4070.2%Chronic bleedings *(n = 135)* Yes43.0%214.3%00.0%23.4%0.313 No13197.0%1285.7%63100.0%5696.6%Blood transfusions *(n = 134)* Yes1511.2%17.1%69.7%813.8%0.681 No11988.8%1392.9%5690.3%5086.2%^a^Classical cut-off for describing the beginning of the expression of *HFE* hemochromatosis in women^b^Daily consumption ≥2 glasses/day or 14 glasses/week in women (World Health Organization definition)\*χ^2^ or Fisher exact test

Analysis of the gender difference in expression of the p.\[Cys282Tyr\];\[Cys282Tyr\] genotype {#Sec8}
---------------------------------------------------------------------------------------------

Our study confirmed that the age at diagnosis was delayed in women in comparison to the men cared for during the same period (52.6 vs. 47.4 y.; *P* \< 0.001). As illustrated in Table [2](#Tab2){ref-type="table"}, the sex ratio decreased significantly with the age at diagnosis, especially after the age of 50 years (χ^2^~linear\ trend~: 10.5; *P* = 0.001). Thus, women represented about 38% of the p.Cys282Tyr homozygous patients diagnosed before the age of 50 (sex ratio = 1.64), 47.3% of patients diagnosed between 50 and 59 years (sex ratio = 1.12), and 64.6% of patients diagnosed after the age of 60 (sex ratio = 0.55).Table 2Distribution of men and women by age at diagnosisAge at diagnosisTotalMenWomenSex ratio*n*%*n*%  \< 40 y.684261.8%2638.2%1.62 \[40--50\[y.774862.3%2937.7%1.66 \[50--60\[y.914852.7%4347.3%1.12  ≥ 60 y.652335.4%4264.6%0.55Total30116153.5%14046.5%1.15

Baseline characteristics of women according to the pregnancy status {#Sec9}
-------------------------------------------------------------------

The number of pregnancies of the 137 p.Cys282Tyr homozygous hemochromatosis women ranged from zero to six, with an average of 2.4 pregnancies per woman (± 1.3). Nearly 90% of the women in our sample (*n* = 123) had at least one pregnancy before entering the phlebotomy program, with the majority of women having had two (42.3%; *n* = 58) or three (27.0%; *n* = 37) pregnancies. Approximately 15% of the women had four pregnancies or more (15.3%; *n* = 21).

The baseline characteristics and the biological markers of women according to the number of pregnancies (categorised in three groups) are summarised in Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}. As illustrated in Table [1](#Tab1){ref-type="table"}, the age at diagnosis, the proportion of overweight patients and the frequency of alcohol abusers did not differ significantly between the three groups. Similar results were observed for the proportion of patients with previous regular blood donations, chronic bleedings or blood transfusions. At the opposite, a significant association was observed between the number of pregnancies and the proportion of postmenopausal women (*P* = 0.002). Table [3](#Tab3){ref-type="table"} shows that there was no significant difference in iron markers according to the number of pregnancies.Table 3Biological parameters of the p.Cys282Tyr homozygous hemochromatosis women according to the number of pregnancies that women had prior to entry into the phlebotomy programBiological parametersNumber of pregnancies: 0Number of pregnancies: 1 or 2Number of pregnancies: ≥ 3*P*‡MedianIQR^a^MedianIQRMedianIQRTransferrin saturation (%) *(n = 137)*81\[72--89\]78\[65--88\]83\[67--97\]0.998Serum ferritin (μg/L) *(n = 137)*298\[236--529\]414\[279--693\]412\[297--770\]0.293Amount of iron removed (g) *(n = 127)*1.3\[1.1--2.0\]2.51.4--4.0\]2.3\[1.6--3.6\]0.140Hemoglobin (g/dL) *(n = 108)*13.6\[13.3--14.6\]14.0\[13.6--14.5\]13.9\[13.4--14.4\]0.815^a^Interquartile range (\[Quartile 1 -- Quartile 3\])^‡^Mann-Whitney test

Association between pregnancy and iron markers {#Sec10}
----------------------------------------------

The results of linear regression modelling the association between pregnancy and iron markers (SF and AIR, respectively) are summarised in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}. Unlike what one might expect, women having had at least one pregnancy did not present lower iron markers than women with no pregnancy. Indeed, the univariable analysis showed that, in comparison to women with no pregnancy, the SF concentration was not different in women who had one or two pregnancies (*P* = 0.288) nor in women who had three or more pregnancies (*P* = 0.126). Combination of these two modalities provided similar findings (e^β^~≥1\ vs.\ 0\ pregnancy~ = 1.32; 95% confidence interval \[CI\]: 0.88--1.97; *P* = 0.177). Adjustment for potential confounders such as age at diagnosis, alcohol intake and menopausal status did not change the observed trends, whatever the coding used.Table 4Results of the linear regression analysis modelling the association between pregnancies and serum ferritinVariablesUnivariable analysisMultivariable analysise β95% CI*P*e β95% CI*P*No. of pregnancies 01.001.00 1 or 21.25\[0.82--1.91\]0.2881.03\[0.67--1.57\]0.902  ≥ 31.39\[0.91--2.13\]0.1261.02\[0.66--1.57\]0.944Age at diagnosis  \< 60 y.^a^1.001.00  ≥ 60 y.1.35\[1.04--1.73\]0.0261.20\[0.89--1.62\]0.230Body mass index  \< 25 kg/m^2^1.00  ≥ 25 kg/m^2^1.13\[0.86--1.48\]0.387--Alcohol intake Non excessive1.001.00 Excessive^b^2.38\[1.34--4.20\]0.0032.06\[1.11--3.85\]0.023Menopause No1.001.00 Yes1.55\[1.20--2.00\]\< 0.0011.39\[1.03--1.87\]0.032Regular blood donations No1.00 Yes0.84\[0.64--1.11\]0.219--Chronic bleedings No1.00 Yes0.96\[0.46--1.99\]0.904--Blood transfusions No1.00 Yes1.02\[0.69--1.50\]0.938--^a^Classical cut-off for describing the beginning of the expression of *HFE* hemochromatosis in women^b^Daily consumption ≥ 2 glasses/day or 14 glasses/week in women (World Health Organization definition)Univariable analysis for pregnancy: global *P*-value = 0.293Table 5Results of the linear regression analysis modelling the association between pregnancies and the amount of iron removed by phlebotomiesVariablesUnivariable analysisMultivariable analysise β95% CI*P*e β95% CI*P*No. of pregnancies 01.001.00 1 or 21.49\[0.98--2.26\]0.0611.41\[0.99--2.02\]0.058  ≥ 31.51\[0.99--2.31\]0.0581.27\[0.89--1.83\]0.191Age at diagnosis  \< 60 y.^a^1.001.00  ≥ 60 y.1.19\[0.90--1.56\]0.2141.11\[0.86--1.43\]0.415Body mass index  \< 25 kg/m^2^1.00  ≥ 25 kg/m^2^0.96\[0.72--1.27\]0.766--Alcohol intake Non excessive1.001.00 Excessive^b^2.29\[1.32--3.97\]0.0041.32\[0.80--2.19\]0.279Menopause No1.001.00 Yes1.28\[0.97--1.71\]0.0840.92\[0.72--1.19\]0.530Regular blood donations No1.00 Yes1.01\[0.76--1.34\]0.930--Chronic bleedings No1.00 Yes1.01\[0.50--2.05\]0.979--Blood transfusions No1.00 Yes0.98\[0.67--1.43\]0.924--Baseline ferritin1.00\[1.00--1.00\]\< 0.0011.00\[1.00--1.00\]\< 0.001^a^Classical cut-off for describing the beginning of the expression of *HFE* hemochromatosis in women^b^Daily consumption ≥2 glasses/day or 14 glasses/week in women (World Health Organization definition)Univariable analysis for pregnancy: global *P*-value = 0.140

Similar findings were obtained for the second iron marker: AIR (Table [5](#Tab5){ref-type="table"}). The univariable analysis revealed no significant association between pregnancy and AIR. When comparing women who had at least one pregnancy to women with no pregnancy, AIR was even significantly higher (i.e. 1.5 time higher) in women who had at least one pregnancy (e^β^~≥1\ vs.\ 0\ pregnancy~ = 1.50; 95% CI: 1.01--2.23, *P* = 0.047). However, this relationship became non-significant after adjustment for potential confounders (e^β^~≥1\ vs.\ 0\ pregnancy~ = 1.35; 95% CI: 0.96--1.90, *P* = 0.088). The results remained still at the limit of significance after adjustment for age at diagnosis, alcohol consumption, menopausal status and baseline SF level, when comparing women having one or two pregnancies to women having no pregnancy (*P* = 0.058).

Discussion {#Sec11}
==========

Pregnancy has been suggested to be one potential factor responsible for the later manifestation of *HFE* hemochromatosis in women \[[@CR15]--[@CR17]\]. Yet, our work is the first epidemiological study entirely devoted to the analysis of the association between pregnancy and the phenotypic expression of the main *HFE* genotype in humans. Our study confirms that p.Cys282Tyr homozygous women are diagnosed at a later age than men, and thus corroborates the existence of a difference in the expression of this genotype between men and women. Nevertheless, these results do not confirm the protective effect typically attributed to pregnancy to explain the slower iron accumulation in women.

Our study was subject to little selection bias for several reasons. First, it was a cohort study that included prospectively almost all of the p.Cys282Tyr homozygous hemochromatosis women enrolled in a phlebotomy program at our centre over the study period. Second, the rate of missing values for the main explanatory variable (pregnancy) was very low (\~ 2.0%), making our sample fully representative of the p.Cys282Tyr homozygous women who come to medical attention in our area. Finally, we also ensured that the baseline characteristics of women excluded from the multivariable analysis (due to missing values) did not differ from those of included women.

Moreover, iron burden was measured using SF but also AIR, which is the reference method to assess body iron stores \[[@CR26]\]. AIR is a more reliable marker than SF, which may also be increased beyond the real degree of iron burden by secondary causes of hyperferritinaemia as excessive alcohol intake or metabolic or inflammatory syndromes \[[@CR27]\].

Our study was also able to take into account major confounders, as alcohol intake or menopausal status at entry into the phlebotomy program. Nevertheless, we did not have information on the presence of some other factors susceptible to modify the iron burden (iron supplementation during pregnancy, blood losses from labor and delivery, postpartum hemorrhage, pregnancy complications (pre-eclampsia, abruption, placenta previa), importance of menstrual blood losses, \...) \[[@CR28]\]. However, most of these data are not easy to quantify precisely. Some of them may also only have a small effect on iron status, as maternal breastfeeding because its duration (with its consecutive amenorrhea) is in average relatively short and because very little iron is transferred to the milk. We are also aware that it would have been ideal to know the delay between various pregnancies, as well as between the last pregnancy and the beginning of the treatment.

To the best of our knowledge, no epidemiological study has so far been exclusively devoted to the study of the relationship between pregnancy and iron overload in *HFE* hemochromatosis in humans. Some studies have nevertheless shown interest to pregnancy. In a study comparing clinical features of 176 women and 176 matched men \[[@CR14]\], Deugnier et al. mentioned that they found no significant correlation between the number of pregnancies and the hepatic iron concentration or the AIR, but no data were presented. They also observed, through a population-based screening study \[[@CR13]\], that the number of pregnancies did not differ between 23 expressive and 19 non expressive women. More recently, the same team explored pregnancy as a potential confounder in a model assessing the relationship between body mass index and iron burden in *HFE* hemochromatosis \[[@CR29]\]. They found no significant association between the number of pregnancies and AIR (≥ 6 g or \< 6 g) in univariable analysis. All these data are consistent with our results.

Our findings seem quite plausible in the current context of fertility. Given the 2016 French fertility rate estimated at 1.93 children per woman \[[@CR30]\], it is not surprising that iron losses resulting from an average of two pregnancies per woman are not sufficient to protect against this disease. This situation was most likely different in the past when the fertility rate was higher.

During pregnancy, the daily requirements for absorbed iron markedly increase, from approximately 0.8 mg/day in the first trimester to \~ 8 mg/day in the third trimester \[[@CR18], [@CR31]--[@CR33]\]. Globally, for a singleton pregnancy, a woman needs up to one gram of iron to ensure the balance of iron (depending on iron stores at the beginning of gestation). This corresponds to \~ 500 mg for the physiological expansion of haemoglobin mass, \~ 315 mg for the constitution of foetal tissue and placenta and \~ 250 mg for basal losses \[[@CR32], [@CR34], [@CR35]\]. Blood losses at delivery also account to about 150 to 250 mg iron. These additional needs are drawn from the reserves of the mother and are transported to the foetus via the placenta. To cope with extra needs and to replenish the maternal stores, intestinal iron absorption also increases during pregnancy (about approximately 25%) \[[@CR36]\]. A part of iron is also made available from the stopping of menses (although this is not sufficient) and from prophylactic iron supplementation that is usually recommended.

It would have been interesting to compare the amount of iron lost during pregnancy to that lost during menses. For example, it has been shown that healthy women with normal menses lose an average of 26 to 65 mL of blood per cycle \[[@CR37]--[@CR39]\], which corresponds at most to a loss of 1 mg iron per cycle (according to the recent assays performed by Napolitano et al.) (20) \[[@CR38]\]. Therefore, if we consider that the entire childbearing period lasts average of 40 years (from the mean age at menarche (\~ 12 y.) until the mean age at menopause (51 y.)), the total quantity of iron lost due to menses over a lifetime is approximately 520 mg (assuming 13 cycles of 28 days per year). This quantity appears lower than that lost during one pregnancy.

Our findings are also consistent with the results of an experimental study in a mouse model \[[@CR20]\] showing that multiple pregnancies do not reduce body iron stores in *Hfe*^−/−^ mice. This study found that all relevant clinical parameters of hemochromatosis (except TS) were not significantly decreased (or even increased) in multiparous females compared with nulliparous females. The hepatic expression of hepcidin \[[@CR40]\] and its regulator (BMP6) \[[@CR41]\] was reduced in multiparous females, suggesting that the inhibition of intestinal iron absorption was inactivated in response to pregnancy.

Current experimental data suggest that other factors such as hormonal factors may explain the difference in disease expression observed between men and women. Recent findings revealed that the gender difference observed in diseases associated with altered hepcidin expression such as *HFE* hemochromatosis may be explained by the negative regulation of hepcidin transcription by testosterone \[[@CR19]\]. Latour et al. showed that testosterone inhibits hepcidin transcription in mice, via enhancement of epidermal growth factor (EGF) receptors signalling in the liver (knowing that EGF was recently shown to inhibit liver hepcidin synthesis \[[@CR42]\]). The authors stated that the selective inhibition of EGF receptor in male mice stops testosterone-induced repression and clearly increases hepcidin expression. Moreover, castration of male mice enhances hepcidin expression thus lowers iron overload. Therefore this work highlights that testosterone should be one major hormone responsible for the observed gender difference in regulation of iron metabolism.

Conclusions {#Sec12}
===========

Our work challenges an old and well-established, yet unproven, hypothesis that pregnancy slows iron accumulation in women with *HFE* hemochromatosis. Combined with recent experimental data from the literature, our findings clearly show that the effect of pregnancy is not as important as initially announced and that the search for the factors responsible for the gender difference should continue.
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